Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase IV, prospective, randomized, multi-center study to find risk factors of OAB
symptoms relapse in patients who showed therapeutic benefits after 1, 3, or 6 months of
treatment with Tolterodine SR and who then discontinued these antimuscarinics for 3 month.
Patients who have OAB symptoms for 6 or more than 6 months and who show successful treatment
response to 1 month of treatment with Tolterodine SR 4mg will be enrolled and randomized to
1, 3 or 6 months of treatment group. After completion of the treatment, subjects will be
evaluated for changes in OAB symptoms and retreatment rate will be assessed.